Page last updated: 2024-11-04

6-anilino-5,8-quinolinedione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

6-anilino-5,8-quinolinedione: structure given in first source; SRS-A & guanylate cyclase antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-anilino-5,8-quinolinedione : A quinolone that is quinoline-5,8-dione in which the hydrogen at position 6 is replaced by an anilino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3976
CHEMBL ID312487
CHEBI ID78677
SCHEMBL ID970943
MeSH IDM0123590

Synonyms (61)

Synonym
CBIOL_001967
CHEMBL312487 ,
chebi:78677 ,
BRD-K62792802-001-02-8
BIO1_001231
BIO1_000742
BIO1_000253
BIO2_000443
BIO2_000923
6-(phenylamino)quinoline-5,8-dione
QTL1_000051
BSPBIO_001225
6-(phenylamino)-5,8-quinolinedione
6-anilinoquinoline-5,8-quinone, >=95% (tlc), solid
IDI1_002198
NCGC00163462-01
NCGC00163462-02
ly 83583
ly-83583
5,8-quinolinedione, 6-(phenylamino)-
6-anilino-5,8-quinolinedione
KBIO2_000565
KBIO2_003133
KBIO2_005701
KBIO3_001009
KBIO3_001010
KBIOGR_000565
KBIOSS_000565
NCGC00163462-03
HMS1990M07
BRD-K62792802-001-03-6
91300-60-6
HMS1792M07
HMS1362M07
6-anilinoquinoline-5,8-dione
A843796
bdbm50326696
6-phenylamino-quinoline-5,8-dione
ly83583
ksc-293-084
KUC111778N
FT-0620949
GXIJYWUWLNHKNW-UHFFFAOYSA-N
6-anilinoquinoline-5,8-quinone
SCHEMBL970943
HMS3403M07
HMS3649K07
4-anilino-1-hydroxybenzene
mfcd00210756
DTXSID60238488
AKOS027320589
Q27147906
phenylamino)-5,8-quinolinedione, 6-(
TD9FS56333
5,8-dihydro-5,8-dioxo-6-(phenylamino)quinoline
SR-01000946579-1
sr-01000946579
MS-23538
SB71418
CS-W014102
HY-W013386

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Doubling the dosage of drug (2-mg/kg bolus, 6 mg/kg."( In vivo and in vitro studies of a putative inhibitor of cyclic guanosine 3',5'-monophosphate production.
Brandt, MA; Conrad, KP, 1991
)
0.28
" Moreover, the soluble guanylate cyclase inhibitor LY-83583 inhibited in a dose-response manner the effects of the NO donors."( The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokine-deprived human eosinophils.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
0.29
" Moreover, oxyhemoglobin, a scavenger of free NO, suppressed the chemotactic effect of SNAP, whereas LY-83583, a soluble guanylate cyclase inhibitor, inhibited the SNAP-mediated chemotaxis in a dose-response manner."( Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
0.29
" Nitroprusside, atriopeptin II and 8-Br-cGMP all increased renin release but the dose-response relationships were biphasic."( Cyclic GMP-linked pathway for renin secretion.
Abu-Kishk, RA; D'Aloia, MA; Lush, DJ; Noble, AR; Williams, BC, 1994
)
0.29
"5 g resting tensions, NOS inhibitors shifted the ACh dose-response curve to the right."( Mechanical stretch reveals different components of endothelial-mediated vascular tone in rat aortic strips.
Bani, D; Ciuffi, M; Failli, P; Franchi-Micheli, S; Mazzetti, L; Zilletti, L, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 4.6.1.2 (guanylate cyclase) inhibitorAn EC 4.6.* (P-O lyase) inhibitor that interferes with the action of enzyme guanylate cyclase (EC 4.6.1.2).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
quinolone
aminoquinolineAny member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
p-quinonesA quinone in which the two oxo groups of the quinone are located para to each other on the 6-membered quinonoid ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency31.83260.004023.8416100.0000AID485290
Chain A, Ferritin light chainEquus caballus (horse)Potency35.48135.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency1.06100.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency24.80330.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency7.07950.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency19.95260.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency7.07950.016525.307841.3999AID602332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.81460.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency0.89130.125912.234435.4813AID1458
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency1.58491.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Guanylate cyclase soluble subunit beta-2Homo sapiens (human)IC50 (µMol)1.00001.00001.00001.0000AID1631031
Guanylate cyclase soluble subunit alpha-2Homo sapiens (human)IC50 (µMol)1.00001.00001.00001.0000AID1631031
Guanylate cyclase soluble subunit alpha-1Homo sapiens (human)IC50 (µMol)1.00001.00001.00001.0000AID1631031
Guanylate cyclase soluble subunit beta-1Homo sapiens (human)IC50 (µMol)1.00001.00001.00001.0000AID1631031
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
cGMP biosynthetic processGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
positive regulation of nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
regulation of blood pressureGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
positive regulation of nitric oxide mediated signal transductionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
relaxation of vascular associated smooth muscleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
retrograde trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cGMP biosynthetic processGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide mediated signal transductionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
blood circulationGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
nitric oxide-cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cellular response to nitric oxideGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
trans-synaptic signaling by nitric oxide, modulating synaptic transmissionGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cGMP-mediated signalingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
response to oxygen levelsGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
GTP bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
metal ion bindingGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
adenylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
GTP bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
heme bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
signaling receptor activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
protein-containing complex bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
metal ion bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
cytidylate cyclase activityGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
Hsp90 protein bindingGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytosolGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit beta-2Homo sapiens (human)
cytosolGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit alpha-2Homo sapiens (human)
cytosolGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGuanylate cyclase soluble subunit alpha-1Homo sapiens (human)
cytosolGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
guanylate cyclase complex, solubleGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
presynaptic active zone cytoplasmic componentGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
glutamatergic synapseGuanylate cyclase soluble subunit beta-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID513556Increase of SUV3 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513553Increase of HMI1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513563Decrease of HOS1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID175494Inhibitory activity on acetylcholine-induced vasorelaxation of phenylephrine-precontracted rat aorta with intact endothelium1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
6-arylamino-5,8-quinolinediones and 7-arylamino-5,8-isoquinolinediones as inhibitors of endothelium-dependent vasorelaxation.
AID513564Decrease of YDR222W gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513560Increase of MAM1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513562Decrease of RIM11 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513557Increase of PET111 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID1631031Inhibition of soluble guanylate cyclase (unknown origin)2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Analysis of quinolinequinone reactivity, cytotoxicity, and anti-HIV-1 properties.
AID513555Increase of YDR514C gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID180024Percent of maximal acetylcholine (ACh)-induced vasorelaxation of the rat aorta1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
6-arylamino-5,8-quinolinediones and 7-arylamino-5,8-isoquinolinediones as inhibitors of endothelium-dependent vasorelaxation.
AID513552Increase of FMP38 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513567Decrease of SGN1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513561Decrease of FET4 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513565Decrease of YKR75C gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513569Inhibition of yeast Guf12006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID506755Inhibition of rapamycin-mediated cytostatic effect in Saccharomyces paradoxus after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID513568Decrease of YMD8 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID506753Inhibition of rapamycin-mediated cytostatic effect in Saccharomyces mikatae after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID513558Increase of MDL1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID513566Decrease of YJL051W gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID506751Inhibition of rapamycin-mediated cytostatic effect in Saccharomyces bayanus after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID513559Increase of MRPS28 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID506749Inhibition of rapamycin-mediated cytostatic effect in yeast RM11-1a after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID513554Increase of YRR1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID506747Inhibition of 50 nM rapamycin-mediated cytostatic effect in yeast BY4742 after 48 to 96 hrs2007Nature chemical biology, Jun, Volume: 3, Issue:6
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.
AID513551Increase of GUF1 gene expression in wild-type Saccharomyces cerevisiae transformed with overexpression plasmids by microarray2006Nature chemical biology, Feb, Volume: 2, Issue:2
Microarray-based method for monitoring yeast overexpression strains reveals small-molecule targets in TOR pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (357)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (5.04)18.7374
1990's197 (55.18)18.2507
2000's114 (31.93)29.6817
2010's23 (6.44)24.3611
2020's5 (1.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.59 (24.57)
Research Supply Index5.90 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.27%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other364 (99.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]